Teva Gets Court Decision Regarding Generic Prevacid SoluTab
TEVA | Quote | Chart | News | PowerRating -- Teva Pharmaceutical Industries announced that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid (Lansoprazole) SoluTab.
In a release, the Company noted that the Court found that its generic lansoprazole orally disintegrating tablets do not infringe U.S. Patent No. 5,464,632. Teva intends to complete an analysis of the decision before deciding upon its next course of action.
Annual sales of the brand product were approximately $500 million in the United States for the twelve months that ended June 30, based on IMS sales data.
((Comments on this story may be sent to health@closeupmedia.com))
For full details on Teva Pharm Ind (TEVA) TEVA. Teva Pharm Ind (TEVA) has Short Term PowerRatings at TradingMarkets. Details on Teva Pharm Ind (TEVA) Short Term PowerRatings is available at This Link.
- Israeli Teva gets rights for multiple sclerosis drug in Nordic, Baltic states - 02/09/10
- BiomedReports: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI) - 02/09/10
- Teva and Active Biotech amend marketing and distribution agreement - 02/09/10
- FDA Accepts Teva's XM02 for Neutropenia - 02/09/10
- Teva extends oral laquinimod marketing rights: Teva and Active Biotech amended their marketing and distribution agreement for or - 02/08/10
- More News >>


